Skip to content
AnalystLens

AbbVie Inc. 8-K Report, Financial Results (Oct 3, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 3, 2025
Period End
October 3, 2025
Security
ABBV
In the record · 2016–202610-K1110-Q328-K163

ABBV filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 163 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’16Nov ’16
  2. Material agreement8-K · May ’20May ’20
  3. Leadership change8-K · Nov ’22Nov ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed October 3, 2025. Cited figures are marked; the original filing is the authoritative source.

AbbVie Inc. (ABBV) has filed an 8-K report on October 3, 2025, providing a preliminary update on its third-quarter 2025 financial results.

The company anticipates a significant pre-tax charge of $2.7 billiona related to acquired In-Process Research & Development (IPR&D) and milestones. This expense is expected to have an unfavorable impact of $1.50 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. Investors should note that these results are preliminary and subject to finalization.

This substantial IPR&D and milestone expense, which AbbVie does not typically forecast due to its unpredictable nature, will adjust the company's full-year 2025 adjusted diluted EPS guidance to a range of $10.38b - $10.58. The third-quarter 2025 adjusted diluted EPS guidance, including this charge, is now projected between $1.74 - $1.78. The company emphasizes that these are estimates and actual results may vary.

02—Key points

Key Highlights

  1. AbbVie anticipates a $2.7 billion pre-tax charge for acquired IPR&D and milestones in Q3 2025.
  2. This charge will negatively impact Q3 2025 GAAP and adjusted non-GAAP diluted EPS by an estimated $1.50 per share.
  3. Acquired IPR&D and milestone expenses are inherently unpredictable and not usually forecasted by AbbVie.
  4. Full-year 2025 adjusted diluted EPS guidance is revised to $10.38 - $10.58, incorporating the Q3 charge.
  5. Q3 2025 adjusted diluted EPS guidance is now projected to be between $1.74 - $1.78, including the impact of the expense.
  6. The reported Q3 results are preliminary and subject to final financial closing procedures.
  7. Exhibit 99.1 contains detailed guidance, including the estimated acquired IPR&D and milestones expense.

03—Questions

Frequently Asked Questions

  1. What is the primary reason for the expected negative impact on AbbVie's Q3 2025 earnings?

    The primary reason is a significant pre-tax charge of $2.7 billion related to acquired In-Process Research & Development (IPR&D) and milestones. This expense is related to asset acquisitions, collaborations, or licensing agreements.

  2. How will this acquired IPR&D and milestone expense affect AbbVie's earnings per share (EPS)?

    The company expects this expense to unfavorably impact both GAAP and adjusted non-GAAP diluted earnings per share by approximately $1.50 per share for the third quarter of 2025. This also leads to a revision of the full-year 2025 adjusted diluted EPS guidance.

  3. Has AbbVie's full-year 2025 adjusted EPS guidance been updated?

    Yes, AbbVie's full-year 2025 adjusted diluted earnings per share guidance has been revised to a range of $10.38 - $10.58, which now includes the estimated impact of the acquired IPR&D and milestones expense incurred in the third quarter.

  4. Are the reported Q3 2025 results final?

    No, the results for the quarter ended September 30, 2025, are preliminary estimates and have not been finalized. They are subject to the company's financial statement closing procedures, and there is no assurance that the final results will not differ from these estimates.

04—Continue

← View all 8-K filings